Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Sets Up New Taskforce to Promote Access to Japanese Drugs in Asia
September 24, 2019
- Nearly 80% of Japanese Support Insurance Coverage for High-Priced Drugs: Nonprofit Survey
September 18, 2019
- Strengthening Regulatory Science Will Accelerate Innovation in Drug Discovery: JPMA President
September 10, 2019
- Bristol-Myers CEO Caforio Named New PhRMA Chair, Tokyo Visit in October
September 6, 2019
- Number of Sales Reps in Japan Falls Below 60,000 in FY2018, Records 5 Consecutive Years of Decline
August 30, 2019
- Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
- Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
- Lab Test Group Seeks Better Reimbursement Rules for Cancer Gene Panel Testing
August 21, 2019
- Sales Rose Only Slightly, but Drug Wholesalers Still Improved Profit Rates in FY2018: JPWA
August 16, 2019
- Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
- OTC Groups Call for Enhancing Self-Medication Tax Break, Submit Request
July 19, 2019
- Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
- FPMAJ Asks Member Drug Makers to Conduct Self-Inspections to Ensure Stable Supplies
July 11, 2019
- Generic Association Aims to Contribute to Pre-Symptomatic and Preventive Care: New Industry Vision
July 9, 2019
- JPMA Pushing Teleworking for Member Companies
July 5, 2019
- Generic Use Rate at 74.0% in FY2018: JGA
July 1, 2019
- Govt’s 2019 Honebuto Policy Generally in Line with JPMA Views: President
June 28, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
- OTC Group Unveils Reform Requests for Self-Medication Tax Break
June 25, 2019
- Further Pricing Discussions Needed for Pricey Products beyond Kymriah: JMA Chief
June 25, 2019
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…